Chronic myeloid leukemia stem cells and developing therapies.

abstract：:Various types of cytokines have been used in in vitro experiments to generate cytokine-induced killer (CIK) cells that are reactive to patient acute myeloid leukemia (AML) cells. Of these CIK cells, interleukin-2 (IL-2)-activated peripheral blood mononuclear cells, i.e., lymphokine-activated killer (LAK) cells, with t...

journal_title：Leukemia & lymphoma

authors： Kaneko T,Fusauch Y,Kakui Y,Okumura K,Mizoguchi H,Oshimi K

更新日期：1994-07-01 00:00:00

abstract：:Respiratory viral pathogens are a common cause of morbidity in patients with hematologic malignancies. Sensitive molecular assays have increased the detection of common respiratory viruses and expanded the panel of detectable viruses. Both a rapid viral culture with direct fluorescence antibody (DFA) staining and a PC...

journal_title：Leukemia & lymphoma

authors： Murali S,Langston AA,Nolte FS,Banks G,Martin R,Caliendo AM

更新日期：2009-04-01 00:00:00

abstract：:Population level survival of patients with myelodysplastic syndromes (MDS) treated with hypomethylating agents (HMA) is inferior to clinical trials. Using SEER-Medicare data, we identified 2086 MDS patients diagnosed in 2004-13, aged ≥66 years at diagnosis, and receiving ≥1 HMA cycle after 2005. We used multivariate l...

journal_title：Leukemia & lymphoma

authors： Zeidan AM,Hu X,Zhu W,Stahl M,Wang R,Huntington SF,Giri S,Bewersdorf JP,Podoltsev NA,Gore SD,Ma X,Davidoff AJ

更新日期：2020-02-01 00:00:00

abstract：:We investigated the possibility of immunotherapy for multiple myeloma (MM) using myeloma-specific cytotoxic T lymphocytes (CTLs) that were stimulated in vitro by dendritic cells (DCs) pulsing with purified and optimized myeloma lysates. CD14(+) cells were cultured in the presence of GM-CSF and IL-4. On day 6, the imma...

journal_title：Leukemia & lymphoma

authors： Lee JJ,Choi BH,Kang HK,Park MS,Park JS,Kim SK,Pham TN,Cho D,Nam JH,Kim YJ,Rhee JH,Yang DH,Kim YK,Kim HJ,Chung IJ

更新日期：2007-10-01 00:00:00

abstract：:An increasing incidence of Pneumocystis jiroveci pneumonia (PCP) in patients with B-cell non-Hodgkin lymphoma (B-NHL) receiving rituximab treatment has been reported. We reviewed patients with B-NHL who underwent chemotherapy from 2004 to 2008 at our institution to identify risk factors for PCP development during and ...

journal_title：Leukemia & lymphoma

authors： Hashimoto K,Kobayashi Y,Asakura Y,Mori M,Azuma T,Maruyama D,Kim SW,Watanabe T,Tobinai K

更新日期：2010-10-01 00:00:00

abstract：:Relative risks of treatment-emergent adverse events (TEAEs) and related hospitalization is most accurate when accounting for treatment exposure. AZA-AML-001 showed azacitidine (AZA) prolonged overall survival versus conventional care regimens (CCR) in older patients (≥65 years) with acute myeloid leukemia (AML) by 3.9...

journal_title：Leukemia & lymphoma

authors： Seymour JF,Döhner H,Minden MD,Stone R,Gambini D,Dougherty D,Beach CL,Weaver J,Dombret H

更新日期：2017-06-01 00:00:00

abstract：:The purpose of this study was to evaluate the role of 18F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography-computed tomography (PET-CT) in detecting relapse in patients with primary gastric lymphoma (PGL) post-treatment. Data of 39 previously treated patients with PGL (age: 50.3 ± 13.8 years; male: 24) who ...

journal_title：Leukemia & lymphoma

authors： Sharma P,Suman SK,Singh H,Sharma A,Bal C,Malhotra A,Kumar R

更新日期：2013-05-01 00:00:00

abstract：:In classical reduced-intensity conditioning (RIC) regimens, including the fludarabine and busulphan (BF) combination, sirolimus and tacrolimus (SIR-TAC) as graft vs host disease (GVHD) prophylaxis has shown acceptable results. The outcomes of SIR-TAC in a more intense RIC regimen as Thiotepa-fludarabine-busulfan (TBF)...

journal_title：Leukemia & lymphoma

authors： Fox ML,García-Cadenas I,Pérez AM,Villacampa G,Piñana JL,Ortí G,Montoro J,Roldán E,Bosch Vilaseca A,Martino R,Salamero O,Saavedra S,Hernandez-Boluda JC,Esquirol A,Sierra J,Sanz J,Solano C,Bosch F,Barba P,Valcarcel D

更新日期：2020-08-01 00:00:00

abstract：:Treatment of hairy cell leukemia (HCL), a disease first described in 1958, has evolved from splenectomy, which resulted in a normalization of blood counts in about 41% of patients and an improvement in the remaining 59% of patients but with a time to failure of only approximately 19 months, through treatment in the ea...

journal_title：Leukemia & lymphoma

authors： Golomb HM

更新日期：2011-06-01 00:00:00

abstract：:FB2 is a novel Abl/Src dual tyrosine kinase inhibitor which is designed to overcome imatinib resistance. Besides imatinib-sensitive cell lines (K562), FB2 significantly inhibited the growth of imatinib-resistant cell lines of different resistance mechanisms (K562/G5.0 and K562/G01), and decreased the expression of aut...

journal_title：Leukemia & lymphoma

authors： Liu H,Li H,Feng Z,Tai J,Meng Y,Wang H,Xin H,Zhang S,Zuo M,Zhang Y,Chen X

更新日期：2009-03-01 00:00:00

abstract：:HMG-CoA Reductase inhibitors (statins) induce apoptosis in acute myeloid leukemia (AML) cells in vitro; however, the concentrations associated with cell death in AML cells are higher than those clinically tolerated during prolonged therapy. We therefore wished to determine whether short exposures to lovastatin might i...

journal_title：Leukemia & lymphoma

authors： Burke LP,Kukoly CA

更新日期：2008-02-01 00:00:00

abstract：:Central to discovering novel approaches to treating leukemias and lymphomas is a clear understanding of the signaling networks which lead to unchecked cell cycle progression, proliferation, and survival. Cyclic-adenosine monophosphate (cAMP) responsive element-binding protein (CREB) represents a critical integrator of...

journal_title：Leukemia & lymphoma

authors： Mitton B,Cho EC,Aldana-Masangkay GI,Sakamoto KM

更新日期：2011-11-01 00:00:00

abstract：:Indolent lymphomas primarily involving the skeleton (iPBL) represent < 1% of all primary bone lymphomas. The management and prognosis have not been previously described. Patients with primary and secondary iPBL were selected from an international database of 499 patients with a histopathological diagnosis of non-Hodgk...

journal_title：Leukemia & lymphoma

authors： Govi S,Christie D,Mappa S,Marturano E,Bruno-Ventre M,Messina C,Medina EA,Porter D,Radford J,Heo DS,Park Y,Pro B,Jayamohan J,Pavlakis N,Zucca E,Gospodarowicz M,Ferreri AJ,International Extranodal Lymphoma Study Group.

更新日期：2014-08-01 00:00:00

abstract：:In this prospective, multicenter, non-randomized study for patients with stage I-II Hodgkin lymphoma, group 1 (without risk-factors [RF]) had three cycles of ABVD chemotherapy (adriamycin, bleomycin, vinblastine, and dacarbazine) and group 2 (any of bulk, extranodal site, >3 regions, raised erythrocyte sedimentation r...

journal_title：Leukemia & lymphoma

authors： Wirth A,Grigg A,Wolf M,Goldstein D,Johnson C,Davis S,Dutu G,Kypreos P,Smith C,Kneebone A,Herzberg M,Joseph D,Catalano J,Roos D,Stone J,Reynolds J

更新日期：2011-05-01 00:00:00

abstract：:We describe an 8 year old boy who had received chemotherapy for an acute promyelocytic leukemia and developed a secondary leukemia 27 months after the diagnosis of this first malignancy. Blasts cells were positive for cytoplasmic markers CD22, CD3 and myeloperoxidase. Cell surface T and myeloid-associated markers were...

journal_title：Leukemia & lymphoma

authors： Felice MS,Rossi J,Gallego M,Zubizarreta PA,Cygler AM,Alfaro E,Sackmann-Muriel F

更新日期：1999-07-01 00:00:00

abstract：:Primary non-Hodgkin's lymphoma of bone is uncommon and usually manifests clinically as localized bone pain. Here we report a woman who presented with hypercalcemic crisis and extensive investigation revealed a primary multifocal lymphoma of bone. The course of the disease was very aggressive and despite intensive supp...

journal_title：Leukemia & lymphoma

authors： Evron E,Goland S,Klepfish A,Malnick SD,Sokolowski N,Sthoeger ZM

更新日期：1999-06-01 00:00:00

abstract：:We addressed the prognostic impact of cell-of-origin (COO), MYC and Bcl-2 overexpression as well as isolated MYC rearrangement among 111 patients with limited stage diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiation therapy (RT) after a metabolic complete response to immunochemotherapy. With a ...

journal_title：Leukemia & lymphoma

authors： Augustyn A,Medeiros LJ,Ludmir EB,Gunther J,Fang P,Li S,Ok CY,Bankston ME,Verma V,Pasalic D,Ahmed S,Nastoupil LJ,Westin JR,Strati P,Neelapu SS,Nair R,Steiner RE,Iyer SP,Rodriguez A,Fayad LE,Flowers CR,Dabaja BS,

更新日期：2021-01-22 00:00:00

abstract：:PTK787/ZK222584 (vatalanib), an orally active inhibitor of vascular endothelial growth factor receptors (VEGFRs), was evaluated in this phase II study of 20 patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients received once-daily PTK787/ZK222584 at a target dose of 1250 mg. Eighteen patien...

journal_title：Leukemia & lymphoma

authors： Brander D,Rizzieri D,Gockerman J,Diehl L,Shea TC,Decastro C,Moore JO,Beaven A

更新日期：2013-12-01 00:00:00

abstract：:Chronic exposure to high concentrations of benzene is associated with an increased incidence of myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Studies of patients occupationally exposed to benzene show a pattern of cytogenetic aberrations involving loss of all or part of chromosomes 5 and/or 7 as...

journal_title：Leukemia & lymphoma

authors： Stillman WS,Varella-Garcia M,Irons RD

更新日期：1999-10-01 00:00:00

abstract：:The objective of this study was to assess the reciprocal association between non-Hodgkin lymphoma (NHL) and Merkel cell carcinoma (MCC) using the data of four Nordic Cancer Registries. Data for this study were drawn from the Danish, Finnish, Norwegian, and Swedish cancer registries. Standardized incidence ratios (SIRs...

journal_title：Leukemia & lymphoma

authors： Koljonen V,Rantanen M,Sahi H,Mellemkjær L,Hansen BT,Chen T,Hemminki K,Pukkala E

更新日期：2015-01-01 00:00:00

abstract：:This study was designed to evaluate the efficacy and toxicity of dose intensifying DHAP (dexamethasone, cytarabine and cisplatin) salvage chemotherapy by adding mitoxantrone with GM-GSF support in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). From March 1992 to January 1995, 22 patients with inter...

journal_title：Leukemia & lymphoma

authors： Haq R,Sawka CA,Franssen E,Berinstein NL

更新日期：1999-11-01 00:00:00

abstract：:2-Chlorodeoxyadenosine (2-CdA) is associated with prolonged suppression of CD4 lymphocytes. Cases of tuberculosis or mycobacterium avium intracellulare complex (MAC) infection complicating 2-CdA administration have not been reported despite the low CD4 counts. We report a patient with Hairy Cell Leukaemia (HCL) who de...

journal_title：Leukemia & lymphoma

authors： Broady R,Roberts S,Hawkins T

更新日期：2000-02-01 00:00:00

abstract：:There is no doubt that human B cell lymphoma does not elicit a clinically sufficient T cell mediated immune response that results in tumor rejection. However, the mechanisms leading to this lack of T cell recognition and effector function are still not fully understood. Many potential mechanisms such as "ignorance" in...

journal_title：Leukemia & lymphoma

authors： Schultze JL

更新日期：1999-01-01 00:00:00

abstract：:Follicular lymphoma is an indolent and usually incurable disease. It has been, therefore, traditionally approached either by watch and wait or with single-agent treatments with the purpose of maintaining a good quality of life for a prolonged time. The emergence of more aggressive regimens including polychemotherapy, ...

journal_title：Leukemia & lymphoma

authors： Feuerlein K,Zucca E,Ghielmini M

更新日期：2009-03-01 00:00:00

abstract：:Sensitivity to doxorubicin (DOX) and expression of intracellular endogenous TNF (enTNF) or manganous superoxide dismutase (MnSOD) activity were found to be inversely correlated in leukemic cells from 19 patients (6 acute lymphoblastic leukemia, 13 acute myeloblastic leukemia). In a case with acquired resistance to che...

journal_title：Leukemia & lymphoma

authors： Watanabe N

更新日期：1998-08-01 00:00:00

abstract：:The association of chronic lymphocytic leukemia (CLL) with essential thrombocythemia (ET) is an extremely rare event and until now 3 patients with such coexistence have been reported in the literature. We report a 77-year-old white woman in whom these two disorders were diagnosed concomitantly on the basis of peripher...

journal_title：Leukemia & lymphoma

authors： Robak T,Urbańska-Ryś H,Góra-Tybor J,Wawrzyniak E,Korycka A,Bartkowiak J,Kordek R,Polliack A

更新日期：2003-08-01 00:00:00

abstract：:Morbidity, mortality and discomfort related to gastrectomy has led some investigators to treat patients with stage I-II primary gastric high-grade lymphoma (PGL) with a conservative strategy. Here we report a retrospective series of 21 patients with PGL treated with primary chemotherapy alone or followed by radiation ...

journal_title：Leukemia & lymphoma

authors： Ferreri AJ,Cordio S,Ponzoni M,Villa E

更新日期：1999-05-01 00:00:00

abstract：:A 31-year-old woman with acute myeloblastic leukemia (AML) underwent allogeneic peripheral blood stem cell transplant (PBSCT). On day +274 following transplantation, the patient had severe chest pain, high-grade fever, and general fatigue. Electrocardiographic examination revealed ST segment elevation, and echocardiog...

journal_title：Leukemia & lymphoma

authors： Aoyama Y,Nakao Y,Ohta K,Sakai T,Nakamae H,Yamamura R,Yamane T,Hino M

更新日期：2004-02-01 00:00:00

abstract：:The emergence of radioimmunotherapy (RIT) provides a new therapeutic approach in which monoclonal antibodies directed against tumor-specific antigens are used to target therapeutic radioisotopes to sites of disseminated disease. The target cell is eliminated and adjacent tumor cells, to which antibody has not bound, a...

journal_title：Leukemia & lymphoma

authors： Bischof Delaloye A

更新日期：2003-01-01 00:00:00

abstract：:In chronic myeloid leukemia (CML), experimental studies using synthetic peptides identical to the bcr-abl fusion region have revealed the capability of specific peptides to bind to human leukocyte antigen (HLA) class I molecules (HLA-A2, A3, A11, B8) and class II molecules (HLA-DR1, DR2, DR3, DR4 and DR11). Individual...

journal_title：Leukemia & lymphoma

authors： Chhaya SU

更新日期：2006-02-01 00:00:00